Skip to main content
. 2017 Sep 15;11(5):721–727. doi: 10.5009/gnl17209

Fig. 1.

Fig. 1

Patient disposition.

RAVs, resistance-associated variants; RVRs, rapid virologic responses; ETRs, end-of-treatment responses; SVR12, sustained virologic responses at 12 weeks; DCV, daclatasvir; ASV, asunaprevir; LDV/SOF, ledipasvir/sofosbuvir; SOF, sofosbuvir; RBV, ribavirin.